Under the terms of the agreement Abbott receives a non-exclusive license to MethylPlex for in vitro molecular diagnostics to detect the presence or risk of prostate, bladder and colon cancer for screening and non-screening indications.
Abbott also obtains a non-exclusive license for non-screening applications with other diseases and options to colon cancer biomarkers developed in collaboration with Rubicon.
James Koziarz, acting president and CEO of Rubicon, said: “This license is a significant validation of the MethylPlex technology as an effective, simple, automatable method for detecting cancer using DNA methylation in patient plasma.
“The collaboration between Rubicon and Abbott has been very productive with both parties making significant contributions towards development and commercialization of in vitro diagnostic products that employ MethylPlex biomarkers and assays. We look forward to continuing our joint efforts under our collaboration and developing leading edge products.”